Jason Gotlib

Clinical Focus

• Hematology

Department

• Cancer > Hematology

Honors and Awards

• NIH K23 Mentored Patient-Oriented Research Career Development Award (#HL04409), National Institutes of Health (2001-2006)
• Hematology Division Faculty Teaching Award, Stanford Division of Hematology/Department of Medicine (2005, 2007, 2009)
• Charles Dorsey Armstrong Award for Excellence in Patient Care, Stanford Internal Medicine Residency Program (1998)

Professional Education

• Board Certification: Hematology, American Board of Internal Medicine (2001)
• SUMC - Graduate Medical Education (2003) CA
• Board Certification: Medical Oncology, American Board of Internal Medicine (2002)
• SUMC - Graduate Medical Education (1998) CA
• SUMC - Graduate Medical Education (1996) CA
• SUMC - Graduate Medical Education (1995) CA
• B.A., Franklin & Marshall College Biology; HAPOS (1990)
• M.D., Stanford Medicine (1995)
• M.S., Stanford Clinical Epidemiology (2003)

Graduate & Fellowship Program Affiliations

• Epidemiology

Research Interests

My research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs

Clinical Trials

• Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Recruiting
• A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients Recruiting
• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome Recruiting
• Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Recruiting
• Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Recruiting
• Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Recruiting
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Recruiting
• Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin Followed By High-Dose Cytarabine Followed By Either Gemtuzumab Ozogamicin or No Additional Therapy in Treating Patients With Previously Untreated De Novo Acute Myeloid Leukemia Recruiting
• Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Recruiting
• Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Recruiting
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) Recruiting
• Gemtuzumab and Combination Chemothearpy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Recruiting
• Integrated Whole-Genome Analysis of Hematologic Disorders Recruiting
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Recruiting
• Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients with Acute Myeloid Leukemia Recruiting
• Phase II Intergroup Clinical Trial For Adolescents & Young Adults With Untreated ALL Recruiting
• Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease Recruiting
• Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Recruiting
• Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Recruiting
• Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (STAR-1) Recruiting
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST) Recruiting
• Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Recruiting
• A Dose-Escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis No longer recruiting
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers No longer recruiting
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib (Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase No longer recruiting
• Biomarker To Evaluate protein Profiles of neutropnic Fever/Infection with Acute or Chronic Leukemias No longer recruiting
• Ph I TG101348 for primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis No longer recruiting
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia No longer recruiting
• Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents No longer recruiting
• Phase 1/2 Study of VELCADE®, Dexamethasone, and Revlimid® Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid in Patients With Previously Untreated Multiple Myeloma (EVOLUTION) Completed
• Study of Intravenously Administered SNS-032 in Patients With Advanced B-Lymphoid Malignancies No longer recruiting
• Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed

Publications

• When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings. Pollyea DA,  George TI, Corless C, Gotlib J.  Am J Hematol.  2009;
• Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Abrahamsson AE,  Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH.  Proc Natl Acad Sci U S A.  2009; 106 (10): 3925-9
• RNAi screen for rapid therapeutic target identification in leukemia patients. Tyner JW,  Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.  Proc Natl Acad Sci U S A.  2009; 106 (21): 8695-700
• Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Korver W,  Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A.  Leukemia.  2009; 23 (9): 1587-97
• On being metachromatic: Mystique and misunderstanding in mastocytosis. Gotlib J,  Am J Hematol.  2009;
• Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Fan AC,  Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW.  Nat Med.  2009; 15 (5): 566-71
• Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Weinberg OK,  Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA.  Blood.  2009; 113 (9): 1906-8
• A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Gotlib J,  Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL.  Am J Hematol.  2009; 84 (1): 15-20
• Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. Medeiros BC,  Gotlib J, Zehnder J.  Leuk Lymphoma.  2009; 50 (5): 851-3
• Gene expression and pathway analysis of immune thrombocytopenic purpura. Sood R,  Wong W, Gotlib J, Jeng M, Zehnder JL.  Br J Haematol.  2008; 140 (1): 99-103
• Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Geron I,  Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH.  Cancer Cell.  2008; 13 (4): 321-30
• Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Gotlib J,  Cools J.  Leukemia.  2008; 22 (11): 1999-2010
• Chronic eosinophilic leukemia/hypereosinophilic syndrome. Gotlib J,  Cancer Treat Res.  2008; 142 69-106
• Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. Lay M,  Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL.  J Mol Diagn.  2006; 8 (3): 330-4
• KIT mutations in mastocytosis and their potential as therapeutic targets. Gotlib J,  Immunol Allergy Clin North Am.  2006; 26 (3): 575-92
• Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Gotlib J,  Cross NC, Gilliland DG.  Best Pract Res Clin Haematol.  2006; 19 (3): 535-69
• A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. Fukumoto JS,  Gotlib J.  Am J Hematol.  2006; 81 (11): 870-4
• Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. Dormady SP,  Mariappan MR, Kao D, Gotlib J.  J Clin Oncol.  2006; 24 (27): 4515-6
• Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Gotlib J,  Acta Haematol.  2005; 114 (1): 7-25
• Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Gotlib J,  Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE.  Blood.  2005; 106 (8): 2865-70
• Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Gotlib J,  Curr Hematol Rep.  2005; 4 (1): 77-84
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S,  Gotlib J.  Semin Cancer Biol.  2004; 14 (1): 23-31
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. Jamieson CH,  Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL.  N Engl J Med.  2004; 351 (7): 657-67
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S,  Gotlib J.  Semin Cancer Biol.  2004; 14 (4): 307-15
• The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib J,  Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE.  Blood.  2004; 103 (8): 2879-91